Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry.

Leukemia & lymphoma - 1 Aug 2017

Baughn Linda B, Sachs Zohar, Noble-Orcutt Klara E, Mitra Amit, Van Ness Brian G, Linden Michael A

Abstract excerpt

Multiple myeloma (MM) is an incurable malignant plasma cell neoplasm. Proteasome inhibitors including Bortezomib (Bz) are used to treat MM, and treatment failure due to drug resistance occurs. Bz-sensitive and -resistant MM cells have distinct immunophenotypic signatures that correlate with clinical outcome. These changes can be identified by fluorescence-based cytometry (FBC), however, FBC is rarely used in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Bortezomib

Share to Cell Line, Tumor

Share to Drug Resistance, Neoplasm

Share to Flow Cytometry

Share to Immunophenotyping

Share to Multiple Myeloma

Source

Open in PubMed Open full text

Identifiers

PMID: 27981867
DOI: 10.1080/10428194.2016.1266621
PMCID: PMC5504883

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry.PMID 27981867Read ↗

Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patientsSemantic proximity Read ↗

Applications of Multiparameter Flow Cytometry in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma PatientsSemantic proximity Read ↗

Defining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistanceSemantic proximity Read ↗

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple MyelomaSemantic proximity Read ↗

Molecular mechanisms in multiple myeloma drug resistance.Semantic proximity Read ↗

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple MyelomaSemantic proximity Read ↗

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.Semantic proximity Read ↗

Characterization of Human B Cell Hematological Malignancies Using Protein-Based ApproachesSemantic proximity Read ↗

Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype.Semantic proximity Read ↗

Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model.Semantic proximity Read ↗

T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple MyelomaSemantic proximity Read ↗

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.